132
Views
2
CrossRef citations to date
0
Altmetric
REVIEW

Treating and Managing Laryngopharyngeal Reflux Disease in the Over 65s: Evidence to Date

Pages 1625-1633 | Received 30 Sep 2022, Accepted 04 Nov 2022, Published online: 13 Nov 2023

References

  • Lechien JR, Akst LM, Hamdan AL, et al. Evaluation and management of laryngopharyngeal reflux disease: state of the art review. Otolaryngol Head Neck Surg. 2019;160(5):762–782. doi:10.1177/0194599819827488
  • Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294(12):1534–1540. doi:10.1001/jama.294.12.1534
  • Mahieu HF. Review article: the laryngological manifestations of reflux disease; why the scepticism? Aliment Pharmacol Ther. 2007;26(Suppl 2):17–24. doi:10.1111/j.1365-2036.2007.03474.x
  • Thomas JP, Zubiaur FM. Over-diagnosis of laryngopharyngeal reflux as the cause of hoarseness. Eur Arch Otorhinolaryngol. 2013;270(3):995–999. doi:10.1007/s00405-012-2244-8
  • Janowska A, Dini V, Oranges T, Iannone M, Loggini B, Romanelli M. Atypical ulcers: diagnosis and management. Clin Interv Aging. 2019;14:2137–2143. doi:10.2147/CIA.S231896
  • Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging. 2007;2(1):85–92. doi:10.2147/ciia.2007.2.1.85
  • Greenwald DA. Aging, the gastrointestinal tract, and risk of acid-related disease. Am J Med. 2004;117 Suppl 5A:8–13.
  • Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101(4Pt 2 Suppl 53):1–78. doi:10.1002/lary.1991.101.s53.1
  • Spantideas N, Drosou E, Bougea A, Assimakopoulos D. Laryngopharyngeal reflux disease in the Greek general population, prevalence and risk factors. BMC Ear Nose Throat Disord. 2015;15(1):7. doi:10.1186/s12901-015-0020-2
  • Kamani T, Penney S, Mitra I, Pothula V. The prevalence of laryngopharyngeal reflux in the English population. Eur Arch Otorhinolaryngol. 2012;269(10):2219–2225. doi:10.1007/s00405-012-2028-1
  • Chen XM, Li Y, Guo WL, Wang WT, Lu M. Prevalence of laryngopharyngeal reflux disease in Fuzhou region of China. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016;51(12):909–913. doi:10.3760/cma.j.issn.1673-0860.2016.12.006
  • Lee YS, Choi SH, Son YI, Park YH, Kim SY, Nam SY. Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease. Eur Arch Otorhinolaryngol. 2011;268(6):863–869. doi:10.1007/s00405-010-1475-9
  • Habermann W, Schmid C, Neumann K, et al. Reflux symptom index and reflux finding score in otolaryngologic practice. J Voice. 2012;26(3):e123–7. doi:10.1016/j.jvoice.2011.02.004
  • Chappity P, Kumar R, Deka RC, Chokkalingam V, Saraya A, Sikka K. Proton pump inhibitors versus solitary lifestyle modification in management of laryngopharyngeal reflux and evaluating who is at risk: scenario in a developing country. Clin Med Insights Ear Nose Throat. 2014;7:1–5. doi:10.4137/CMENT.S13799
  • Youssef TF, Ahmed MR. Treatment of clinically diagnosed laryngopharyngeal reflux disease. Arch Otolaryngol Head Neck Surg. 2010;136(11):1089–1092. doi:10.1001/archoto.2010.165
  • Lechien JR, Hans S, Calvo-Henriquez C, Baudouin R, Saussez S. Laryngopharyngeal reflux may be acute, recurrent or chronic disease: preliminary observations. Eur Arch Otorhinolaryngol. 2022;279(9):4629–4632. doi:10.1007/s00405-022-07426-3
  • Mold JW, Reed LE, Davis AB, et al. Prevalence of gastroesophageal reflux in elderly patients in a primary care setting. Am J Gastroenterol. 1991;86:965–970.
  • Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther. 2000;14(12):1589–1594. doi:10.1046/j.1365-2036.2000.00884.x
  • Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastro- esophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112(5):1448–1456. doi:10.1016/S0016-5085(97)70025-8
  • Klimara MJ, Randall DR, Allen J, Figueredo E, Johnston N. Proximal reflux: biochemical mediators, markers, therapeutic targets, and clinical correlations. Ann N Y Acad Sci. 2020;1481(1):127–138. doi:10.1111/nyas.14366
  • Lechien JR, Saussez S, Harmegnies B, Finck C, Burns JA. Laryngopharyngeal reflux and voice disorders: a multifactorial model of etiology and pathophysiology. J Voice. 2017;31(6):733–752. doi:10.1016/j.jvoice.2017.03.015
  • Lechien JR, De Vos N, Everard A, Saussez S. Laryngopharyngeal reflux: the microbiota theory. Med Hypotheses. 2021;146:110460. doi:10.1016/j.mehy.2020.110460
  • Lechien JR, Chan WW, Akst LM, et al. Normative ambulatory reflux monitoring metrics for laryngopharyngeal reflux: a systematic review of 720 healthy individuals. Otolaryngol Head Neck Surg. 2021;1945998211029831. doi:10.1177/01945998211029831
  • Lechien JR, Bobin F, Dapri G, et al. Hypopharyngeal-esophageal impedance-ph monitoring profiles of laryngopharyngeal reflux patients. Laryngoscope. 2021;131(2):268–276. doi:10.1002/lary.28736
  • Salgado S, Borges LF, Cai JX, Lo WK, Carroll TL, Chan WW. Symptoms classically attributed to laryngopharyngeal reflux correlate poorly with pharyngeal reflux events on multichannel intraluminal impedance testing. Dis Esophagus. 2022;doac041. doi:10.1093/dote/doac041
  • Pilotto A. Aging and upper gastrointestinal disorders. Best Pract Res Clin Gastroenterol. 2004;18:Suppl:73–81. doi:10.1016/j.bpg.2004.06.015
  • Pilotto A, Maggi S, Noale M, et al. Association of upper gastrointestinal symptoms with functional and clinical characteristics in elderly. World J Gastroenterol. 2011;17(25):3020–3026. doi:10.3748/wjg.v17.i25.3020
  • Sonnenberg A, Steinkamp U, Weise A, et al. Salivary secretion in reflux esophagitis. Gastroenterology. 1982;83(4):889–895. doi:10.1016/S0016-5085(82)80021-8
  • Block BB, Kuo E, Zalzal HG, Escobar H, Rose M, Preciado D. In vitro effects of acid and pepsin on mouse middle ear epithelial cell viability and MUC5B gene expression. Arch Otolaryngol Head Neck Surg. 2010;136(1):37–42. doi:10.1001/archoto.2009.199
  • Lee J, Anggiansha A, Anggiansah R, et al. Effects of age on the gastroesoph- ageal junction, esophageal motility, and reflux disease. Clin Gastroenterol Hepatol. 2007;5(12):1392–1398. doi:10.1016/j.cgh.2007.08.011
  • Mei L, Dua A, Kern M, et al. Older age reduces upper esophageal sphincter and esophageal body responses to simulated slow and ultraslow reflux events and post-reflux residue. Gastroenterology. 2018;155(3):760–770.e1. doi:10.1053/j.gastro.2018.05.036
  • Khajanchee YS, Urbach DR, Butler N, et al. Laparoscopic antireflux surgery in the elderly. Surg Endosc. 2002;16(1):25–30. doi:10.1007/s00464-001-8157-z
  • Lechien JR, Saussez S, Muls V, et al. Laryngopharyngeal reflux: evolution and predictive value of symptoms and pH-impedance features on clinical evolution. Otolaryngol Head Neck Surg. 2022;1945998221075009. doi:10.1177/01945998221075009
  • Achem SR, DeVault KR. Gastroesophageal reflux disease and the elderly. Gastroenterol Clin North Am. 2014;43(1):147–160. doi:10.1016/j.gtc.2013.11.004
  • Patti MG, Goldberg HI, Arcerito M, et al. Hiatal hernia size affects lower esoph- ageal sphincter function, esophageal acid exposure, and the degree of mucosal injury. Am J Surg. 1996;171(1):182–186. doi:10.1016/S0002-9610(99)80096-8
  • Su A, Gandhy R, Barlow C, Triadafilopoulos G. Clinical and manometric characteristics of patients with Parkinson’s disease and esophageal symptoms. Dis Esophagus. 2017;30(4):1–6. doi:10.1093/dote/dow038
  • Su Y, Shen L, Zhang F, et al. Laryngopharyngeal pH monitoring in patients with idiopathic pulmonary fibrosis. Front Pharmacol. 2021;12:724286. doi:10.3389/fphar.2021.724286
  • Eryuksel E, Dogan M, Olgun S, Kocak I, Celikel T. Incidence and treatment results of laryngopharyngeal reflux in chronic obstructive pulmonary disease. Eur Arch Otorhinolaryngol. 2009;266(8):1267–1271. doi:10.1007/s00405-009-0922-y
  • Chwiesko A, Kowal-Bielecka O, Sierakowski S. Perspectives on the interlinked nature of systemic sclerosis and reflux disease. Expert Rev Gastroenterol Hepatol. 2019;13(3):213–227. doi:10.1080/17474124.2019.1561274
  • Storr M, Allescher HD. Esophageal pharmacology and treatment of primary motility disorders. Dis Esophagus. 1999;12(4):241–257. doi:10.1046/j.1442-2050.1999.00059.x
  • Jung SY, Park DC, Kim SH, Yeo SG. Role of obesity in otorhinolaryngologic diseases. Curr Allergy Asthma Rep. 2019;19(7):34. doi:10.1007/s11882-019-0865-3
  • Halum SL, Postma GN, Johnston C, Belafsky PC, Koufman JA. Patients with isolated laryngopharyngeal reflux are not obese. Laryngoscope. 2005;115(6):1042–1045. doi:10.1097/01.MLG.0000162656.05715.57
  • Lechien JR, Bobin F, Muls V, et al. Validity and reliability of the reflux symptom score. Laryngoscope. 2020;130(3):E98–E107. doi:10.1002/lary.28017
  • Lee YC, Lee JS, Kim SW, Kwon KH, Eun YG. Influence of age on treatment with proton pump inhibitors in patients with laryngopharyngeal reflux disease: a prospective multicenter study. JAMA Otolaryngol Head Neck Surg. 2013;139(12):1291–1295. doi:10.1001/jamaoto.2013.5556
  • Lechien JR, Finck C, Huet K, et al. Impact of age on laryngopharyngeal reflux disease presentation: a multi-center prospective study. Eur Arch Otorhinolaryngol. 2017;274(10):3687–3696. doi:10.1007/s00405-017-4671-z
  • Lechien JR, Carroll TL, Bobin F, et al. Influence of age and sex on clinical and therapeutic features of laryngopharyngeal reflux. Otolaryngol Head Neck Surg. 2022;166(3):468–476. doi:10.1177/01945998211020284
  • Cervera-Paz FJ, Jordano-Cabrera M. Characterisation of laryngo-pharyngeal reflux disease in old and ageing patients. Acta Otorrinolaringol Esp. 2019;70(3):151–157. doi:10.1016/j.otorri.2018.05.002
  • Becher A, Dent J. Systematic review: aging and gastroesophageal reflux disease symptoms, esophageal function and reflux esophagitis. Aliment Pharmacol Ther. 2011;33(4):450. doi:10.1111/j.1365-2036.2010.04542.x
  • Zhu H, Pace F, Sangaletti O, et al. Features of symptomatic gastroesophageal reflux in elderly patients. Scand J Gastroenterol. 1993;28(3):235–238. doi:10.3109/00365529309096078
  • Karkos PD, Wilson JA. Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review. Laryngoscope. 2006;116(1):144–148. doi:10.1097/01.mlg.0000191463.67692.36
  • Jin X, Zhou X, Fan Z, Qin Y, Zhan J. Meta-analysis of proton pump inhibitors in the treatment of pharyngeal reflux disease. Comput Math Methods Med. 2022;2022:9105814. doi:10.1155/2022/9105814
  • Lechien JR, Muls V, Dapri G, et al. The management of suspected or confirmed laryngopharyngeal reflux patients with recalcitrant symptoms: a contemporary review. Clin Otolaryngol. 2019;44(5):784–800. doi:10.1111/coa.13395
  • Lechien JR, Bobin F, Muls V, et al. The efficacy of a personalised treatment depending on the characteristics of reflux at multichannel intraluminal impedance-pH monitoring in patients with acid, non-acid and mixed laryngopharyngeal reflux. Clin Otolaryngol. 2021;46(3):602–613. doi:10.1111/coa.13722
  • Lechien JR. Clinical update findings about pH-impedance monitoring features in laryngopharyngeal reflux patients. J Clin Med. 2022;11(11):3158. doi:10.3390/jcm11113158
  • Abrahami D, McDonald EG, Schnitzer M, Azoulay L. Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study. BMJ Open. 2020;10(12):e041529. doi:10.1136/bmjopen-2020-041529
  • Yailian AL, Huet E, Charpiat B, et al. Characteristics of pharmacists’ interventions related to proton-pump inhibitors in French hospitals: an observational study. Int J Clin Pract. 2022;2022:9619699. doi:10.1155/2022/9619699
  • Toth JM, Jadhav S, Holmes HM, Sharma M. Prescribing trends of proton pump inhibitors, antipsychotics and benzodiazepines of medicare part d providers. BMC Geriatr. 2022;22(1):306. doi:10.1186/s12877-022-02971-2
  • Kanno T, Moayyedi P. Proton pump inhibitors in the elderly, balancing risk and benefit: an age-old problem. Curr Gastroenterol Rep. 2019;21(12):65. doi:10.1007/s11894-019-0732-3
  • Verhasselt M, Rodriguez A, Dequanter D, Lechien JR. Chronic course, weaning, and awareness of patients with reflux toward proton pump inhibitor therapy. J Voice. 2021. doi:10.1016/j.jvoice.2021.03.002
  • Luo H, Fan Q, Bian T, et al. Awareness, attitude and behavior regarding proton pump inhibitor among medical staff in the Southwest of China. BMC Health Serv Res. 2019;19(1):880. doi:10.1186/s12913-019-4725-6
  • Rameau A, Andreadis K, Bayoumi A, Kaufman M, Belafsky P. Side effects of proton pump inhibitors: what are patients’ concerns? J Voice. 2020;35(5):809.e15–809.e20. doi:10.1016/j.jvoice.2020.01.018
  • Lanas-Gimeno A, Hijos G, Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opin Drug Saf. 2019;18(11):1043–1053. doi:10.1080/14740338.2019.1664470
  • Chapman DB, Rees CJ, Lippert D, Sataloff RT, Wright SC Jr. Adverse effects of long-term proton pump inhibitor use: a review for the otolaryngologist. J Voice. 2011;25(2):236–240. doi:10.1016/j.jvoice.2009.10.015
  • Lin RJ, Sridharan S, Smith LJ, Young VN, Rosen CA. Weaning of proton pump inhibitors in patients with suspected laryngopharyngeal reflux disease. Laryngoscope. 2018;128(1):133–137. doi:10.1002/lary.26696
  • Lechien JR, Bobin F, Muls V, et al. Changes of laryngeal and extralaryngeal symptoms and findings in laryngopharyngeal reflux patients. Laryngoscope. 2021;131(6):1332–1342. doi:10.1002/lary.28962
  • Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500–1511. doi:10.1053/gast.2002.32978
  • Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108(6):905–911. doi:10.1038/ajg.2013.69
  • Lechien JR, Crevier-Buchman L, Distinguin L, et al. Is diet sufficient as laryngopharyngeal reflux treatment? A cross-over observational study. Laryngoscope. 2021. doi:10.1002/lary.29890
  • Desilets AR, Asal NJ, Dunican KC. Considerations for the use of proton-pump inhibitors in older adults. Consult Pharm. 2012;27(2):114–120. doi:10.4140/TCP.n.2012.114
  • Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther. 1996;34(5):185–194.
  • Flouvat B, Delhotal-Landes B, Cournot A, et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol. 1993;36(5):467–469. doi:10.1111/j.1365-2125.1993.tb00398.x